If you or someone close to you is interested in taking part in SIGNAL or you would like additional information, please contact a site near you or the Huntington Study Group (HSG):

**Call:** 1-800-487-7671  
**Email:** info@hsglimited.org  
**Visit:** huntingtonstudygroup.org

Heather Ward, Research Coor.  
VCU Parkinson's and Movement Disorders Center  
Heather.ward@vcuhealth.org  
804-382-0076

**SIGNAL** is a Phase 2 research trial for people who are at risk for Huntington Disease (HD) and have early signs of HD. The study will assess the **safety, tolerability, and effectiveness** of VX15 (a novel monoclonal antibody).

Find a Site Near You:
- Birmingham, AL
- LaJolla, CA
- San Francisco, CA
- Aurora, CO
- Washington, DC
- Atlanta, GA
- Indianapolis, IN
- Iowa City, IA
- Louisville, KY
- Boston, MA
- Ann Arbor, MI
- St. Louis, MO
- New York, NY
- Rochester, NY
- Durham, NC
- Winston-Salem, NC
- Cincinnati, OH
- Columbus, OH
- Toledo, OH
- Nashville, TN
- Houston, TX
- Burlington, VT
- Richmond, VA
- Seattle, WA
- Vancouver, BC

**Reimbursement for time spent during in-person visits**, **Reimbursement for reasonable travel and lodging costs**, **Study related medical care, tests, and study drug provided at no cost**

**NOTE:** VX15 has not been approved by the FDA.

Potential benefits of the drug for HD patients are being investigated with the **SIGNAL** trial.
Why study this antibody in individuals at risk for and with early signs of HD?

- If given early it may delay onset or slow the progression of HD
- This monoclonal antibody is a class of drug that binds to and blocks a molecule that may cause inflammation in the brains of individuals who develop HD as seen in animal models
- It may protect against the inflammation that has been shown to affect the thinking, movement, and behaviors that impact the daily activities of individuals with HD

Advances in HD treatment need your participation

What is different about this research trial?

- First-time use of a monoclonal antibody for potential treatment of HD
- Once-a-month study drug delivery through 60-minute (approximately) intravenous infusion
- Use of advanced brain scan techniques and analyses (MRI and PET)

Join the Huntington Study Group and Vaccinex SIGNAL team and play a role in researching a new approach to HD treatment that may change the course of the disease.

We are looking for people who:

- Are at risk for developing HD
- Have undergone genetic testing
- Are thought to be in the early stages of HD
- Are able to undergo brain scans (MRI and PET)
- Are able to undergo lumbar puncture to collect cerebrospinal fluid (not required to enroll)
- Are able to commit to once/month study visits
- Are 21 years of age or older

Your physician can guide you as to whether you are a candidate for this study.